S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:PIRS

Pieris Pharmaceuticals Stock Forecast, Price & News

$3.26
+0.08 (+2.52%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.98
$3.30
50-Day Range
$3.18
$5.77
52-Week Range
$1.70
$6.15
Volume
1.31 million shs
Average Volume
3.66 million shs
Market Capitalization
$234.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.12
30 days | 90 days | 365 days | Advanced Chart
Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Pieris Pharmaceuticals logo

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PIRS
Employees
117
Year Founded
N/A

Sales & Book Value

Annual Sales
$29.32 million
Book Value
$0.75 per share

Profitability

Net Income
$-37.23 million
Net Margins
-205.44%
Pretax Margin
-202.97%

Debt

Price-To-Earnings

Miscellaneous

Free Float
67,904,000
Market Cap
$234.92 million
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/29/2022

MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

903rd out of 1,390 stocks

Pharmaceutical Preparations Industry

430th out of 673 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

Is Pieris Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pieris Pharmaceuticals stock.
View analyst ratings for Pieris Pharmaceuticals
or view top-rated stocks.

How has Pieris Pharmaceuticals' stock price been impacted by Coronavirus?

Pieris Pharmaceuticals' stock was trading at $2.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PIRS stock has increased by 46.2% and is now trading at $3.26.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 694,000 shares, a decline of 75.4% from the October 31st total of 2,820,000 shares. Based on an average daily trading volume, of 1,250,000 shares, the short-interest ratio is presently 0.6 days. Currently, 1.2% of the company's shares are short sold.
View Pieris Pharmaceuticals' Short Interest
.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Pieris Pharmaceuticals
.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.24). Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 120.25% and a negative net margin of 205.44%. During the same period in the previous year, the firm earned ($0.26) EPS.
View Pieris Pharmaceuticals' earnings history
.

What price target have analysts set for PIRS?

3 Wall Street analysts have issued twelve-month target prices for Pieris Pharmaceuticals' stock. Their forecasts range from $8.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $8.50 in the next twelve months. This suggests a possible upside of 160.7% from the stock's current price.
View analysts' price targets for Pieris Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the following people:
  • Stephen S. Yoder, President, Chief Executive Officer & Director
  • Thomas Bures, Senior VP, Chief Financial & Accounting Officer
  • Hitto Kaufmann, Chief Scientific Officer & Senior Vice President
  • Tim Demuth, Chief Medical Officer & Senior Vice President
  • Ahmed S. Mousa, Secretary, Chief Business Officer & Senior VP

What other stocks do shareholders of Pieris Pharmaceuticals own?

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.84%), Morgan Stanley (2.41%), Invesco Ltd. (2.08%), BlackRock Inc. (1.77%), Two Sigma Investments LP (1.62%) and Two Sigma Advisers LP (1.55%). Company insiders that own Pieris Pharmaceuticals stock include Aquilo Capital Management, Llc and Shane Olwill.
View institutional ownership trends for Pieris Pharmaceuticals
.

Which institutional investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Platinum Investment Management Ltd., Squarepoint Ops LLC, Jane Street Group LLC, BlackRock Inc., HAP Trading LLC, and Credit Suisse AG.
View insider buying and selling activity for Pieris Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Pieris Pharmaceuticals stock?

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Two Sigma Investments LP, Two Sigma Advisers LP, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Cutter & CO Brokerage Inc., Connor Clark & Lunn Investment Management Ltd., and Marshall Wace LLP.
View insider buying and selling activity for Pieris Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $3.26.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals has a market capitalization of $234.92 million and generates $29.32 million in revenue each year. The biotechnology company earns $-37.23 million in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

Pieris Pharmaceuticals employs 117 workers across the globe.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is www.pieris.com.

Where are Pieris Pharmaceuticals' headquarters?

Pieris Pharmaceuticals is headquartered at 255 State Street 9th Floor, Boston MA, 02109.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at (857) 246-8998, via email at [email protected], or via fax at 49-8161-141-1444.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.